Atrial cardiomyopathy (ACM) is a key independent predictor of stroke. The LeAAPS Trial integrates ACM factors to identify high-risk cardiac surgery patients who may benefit from preventative left atrial appendage exclusion.
Learn more about the trial: <a href="https://okt.to/ViH3OM" target="_blank">https://okt.to/ViH3OM</a>
<a href='https://www.linkedin.com/feed/hashtag/?keywords=CardiacSurgery&highligh…; target='_blank'>#CardiacSurgery</a> <a href='https://www.linkedin.com/feed/hashtag/?keywords=Stroke&highlightedUpdat…; target='_blank'>#Stroke</a> <a href='https://www.linkedin.com/feed/hashtag/?keywords=ClinicalTrial&highlight…; target='_blank'>#ClinicalTrial</a>
- Healthcare Professionals
- Patients & Caregivers
- About AtriCure